167 related articles for article (PubMed ID: 15281461)
21. DNA vaccines: capacity to induce auto-immunity and tolerance.
Klinman DM; Takeshita F; Kamstrup S; Takeshita S; Ishii K; Ichino M; Yamada H
Dev Biol (Basel); 2000; 104():45-51. PubMed ID: 11713823
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of CpG motifs in endoflagellar gene (flaB2) and expression vector (VR1012) of leptospiral DNA vaccine].
Dai B; You Z; He P; Wang M; Wang Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):1-4. PubMed ID: 15600164
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulation of Japanese encephalitis vaccine through CpG oligodeoxynucleotides in mice.
Sidhapuriwala JN; Sivalingam SP; Lu J; Moochhala SM
Scand J Immunol; 2006 Oct; 64(4):370-5. PubMed ID: 16970676
[TBL] [Abstract][Full Text] [Related]
24. The use of biological response modifiers in parasitic infections.
Ruitenberg EJ; Buys J; Blomjous FJ; de Jong H; Bernadina W
Dev Biol Stand; 1985; 62():129-38. PubMed ID: 3938740
[No Abstract] [Full Text] [Related]
25. Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.
Bergmann-Leitner ES; Leitner WW; Duncan EH; Savranskaya T; Angov E
Vaccine; 2009 Sep; 27(41):5700-8. PubMed ID: 19576940
[TBL] [Abstract][Full Text] [Related]
26. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis.
Mao D; Kai G; Gaofu Q; Zheng Z; Li Z; Jie W; Jingjing L; Rongyue C
Vaccine; 2006 Jun; 24(23):4942-50. PubMed ID: 16697088
[TBL] [Abstract][Full Text] [Related]
27. CpG oligodinucleotides induce strong humoral and cellular responses to swine streptococcic septicemia vaccine in piglets in vivo.
Linghua Z; Yong G; Xingshan T; Fengzhen Z
Int Immunopharmacol; 2006 Mar; 6(3):342-50. PubMed ID: 16428069
[TBL] [Abstract][Full Text] [Related]
28. [The new generations of vaccines against parasites].
Wedrychowicz H
Wiad Parazytol; 2000; 46(1):21-7. PubMed ID: 16886350
[TBL] [Abstract][Full Text] [Related]
29. DNA vaccines against tropical parasitic diseases.
Da'dara AA; Harn DA
Expert Rev Vaccines; 2005 Aug; 4(4):575-89. PubMed ID: 16117713
[TBL] [Abstract][Full Text] [Related]
30. Co-administration of porcine-specific CpG oligodeoxynucleotide enhances the immune responses to pseudorabies attenuated virus vaccine in newborn piglets in vivo.
Linghua Z; Yong G; Xingshan T; Fengzhen Z
Dev Comp Immunol; 2006; 30(6):589-96. PubMed ID: 16169588
[TBL] [Abstract][Full Text] [Related]
31. [Adjuvants--essential components of new generation vaccines].
Dzierzbicka K; Kołodziejczyk AM
Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510
[TBL] [Abstract][Full Text] [Related]
32. Use of CpG DNA for enhancing specific immune responses.
Davis HL
Curr Top Microbiol Immunol; 2000; 247():171-83. PubMed ID: 10689787
[TBL] [Abstract][Full Text] [Related]
33. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
[TBL] [Abstract][Full Text] [Related]
34. Decreased suppression of immune stimulatory CpG motifs in plant DNA.
Wang Y; Zhou J; Liu B
Immunol Lett; 2007 Dec; 114(2):73-80. PubMed ID: 17889375
[TBL] [Abstract][Full Text] [Related]
35. DNA vaccines and their application against parasites--promise, limitations and potential solutions.
Smooker PM; Rainczuk A; Kennedy N; Spithill TW
Biotechnol Annu Rev; 2004; 10():189-236. PubMed ID: 15504707
[TBL] [Abstract][Full Text] [Related]
36. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
37. Prospects for CpG based immunotherapy in asthma and allergy.
Broide DH
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):217-20; discussion 220-2. PubMed ID: 17393743
[TBL] [Abstract][Full Text] [Related]
38. Role of interferon-gamma during CpG oligodeoxynucleotide-adjuvanted immunization with recombinant proteins.
Rosa DS; Bastos KR; Bargieri DY; Tzelepis F; Nomizo A; Russo M; Soares IS; Rodrigues MM
Vaccine; 2007 Aug; 25(32):6007-17. PubMed ID: 17629370
[TBL] [Abstract][Full Text] [Related]
39. In vivo immunostimulatory effects of CpG ODN in newborn piglets.
Linghua Z; Xingshan T; Fengzhen Z
Mol Immunol; 2007 Feb; 44(6):1238-44. PubMed ID: 16908068
[TBL] [Abstract][Full Text] [Related]
40. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
